News

San Francisco-based biopharma Cytokinetics initiated a Phase 2 clinical trial to evaluate the effect of CK-107 on physical function in patients with chronic obstructive pulmonary disease (COPD). CK-2127107 (CK-107) is a novel fast skeletal muscle troponin activator under development as a potential therapy for COPD, spinal muscular atrophy (SMA), and other conditions. It…

Pulmatrix, a pharmaceutical company focused on developing novel inhaled drugs for lung diseases like chronic obstructive pulmonary disease (COPD), recently released an animated life sciences video to raise awareness about lung diseases and to describe promising new treatments in the company’s drug portfolio. “Millions of people struggle to breathe every…

Four Lung Institute facilities in Tampa, Scottsdale, Nashville and Pittsburg, treat restrictive and obstructive lung diseases using stem cells from the patient’s own body. Gary V., a patient, has seen his quality of life improve since he receive stem cell therapy for chronic obstructive pulmonary disease (COPD). For Gary, “improvement” is…

Results from a Novartis Pharmaceuticals Canada study to assess the company’s Ultibro Breezhaler were published in the New England Journal of Medicine.  Researchers say the results are promising and expected to impact the future management and treatment of patients with chronic obstructive pulmonary disease (COPD). An article describing the findings, “…

GlaxoSmithKline and Innoviva announced positive data from the Phase 3 FULFIL clinical trial evaluating their investigational triple combination therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/IV) in patients with chronic obstructive pulmonary disease (COPD). FULFIL is a randomized, double-blind, multicenter study designed to evaluate the efficacy and safety of a daily dose of the FF/UMEC/IV…

Researchers from the University of Texas Medical Branch (UTMB) at Galveston are studying the latest trends for pulmonary rehabilitation (PR) therapy among older adults with chronic obstructive pulmonary disease (COPD). PR therapy is designed as a comprehensive approach to help patients relieve COPD symptoms and flare-ups while teaching them how…

Pulmonary rehabilitation could reduce the frailty of older people with chronic obstructive pulmonary disease (COPD) suggests a new study published in the journal Thorax.

The clinical stage biopharmaceutical Pulmatrix, recently announced the completion of a pilot study to access the pharmacokinetics of PUR0200 for maintenance treatment of bronchospasms in patients with chronic obstructive pulmonary disease (COPD). The testing of PUR0200, a dry powdered generic of a once-daily, long-acting muscarinic antagonist, was done using healthy volunteers. In Europe,…

Chronic obstructive pulmonary disease (COPD) is currently the third leading cause of death in the United States. But while significant scientific progress is being made, COPD patients face serious challenges when it comes to treatment access, particularly because  treatments costs are high and hospitals have not yet reached recommended standards for COPD care. The startling opinions,…

GlaxoSmithKline (GSK) and Innoviva (INVA) recently published promising data about the Salford Lung Study (SLS) in chronic obstructive pulmonary disease (COPD). The clinical trial demonstrated that Relvar Ellipta (fluticasone furoate and vilanterol) could reduce exacerbations compared to usual care, for people with COPD. Usual care involved long-acting muscarinic antagonists (LAMA), long-acting beta2-agonists…